Wong, A L <br/><br/>
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  May 2015 
 - 998-1005 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdv026  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--administration & dosage<br/>Asia<br/>Biomarkers, Tumor--antagonists & inhibitors<br/>Biotransformation<br/>Carcinoma, Non-Small-Cell Lung--blood<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>ErbB Receptors--genetics<br/>Female<br/>Half-Life<br/>Humans<br/>Lung Neoplasms--blood<br/>Male<br/>Maximum Tolerated Dose<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Molecular Targeted Therapy<br/>Mutation<br/>Phosphorylation<br/>STAT3 Transcription Factor--antagonists & inhibitors<br/>Signal Transduction--drug effects<br/>Treatment Outcome